Literature DB >> 7358847

Determinants of chronic carbon dioxide retention and its correction in humans.

J B Skatrud, J A Dempsey, P Bhansali, C Irvin.   

Abstract

17 patients with chronic ventilatory failure (including 14 with chronic obstructive pulmonary disease) were studied to determine the causes of carbon dioxide retention and the chronic effect of medroxyprogesterone acetate on ventilatory drive and acid-base status. Carbon dioxide retention in patients with high mechanical loads occurred concomitantly with a higher than normal inspiratory effort (mouth occlusion pressure) and normal minute ventilation to carbon dioxide production ratio (Ve/Vco(2)); but with shortened inspiratory time (1.3+/-0.1 vs. 1.8+/-3 s), increased breathing frequency (17+/-1 vs. 14+/-1 breaths/min), low tidal volume (0.57+/-0.03 vs. 0.88+/-0.04 L), and high dead space to tidal volume ratio (0.63+/-0.02 vs. 0.39+/-0.07). Using a randomized application of treatment and placebo conditions, it was shown that 4 wk of medroxyprogesterone acetate caused significant reductions in Paco(2) (from 51+/-1 to 42+/-1 mm Hg) in 10 of 17 patients. This "correction" of Paco(2) in these patients was associated with increases in mouth occlusion pressure (14%), tidal volume (11%), and alveolar ventilation (15%) compared to placebo, although inspiratory time remained shortened. Arterial and lumbar cerebrospinal fluid pH was alkaline compared to placebo in patients who "corrected" Paco(2). No change was noted in lung mechanics or core temperature. Common prerequisites for correction of Paco(2) with medroxyprogesterone acetate treatment were the ability to significantly lower Paco(2) upon acute voluntary hyperventilation and to increase tidal volume rather than breathing frequency in response to the drug. We attribute chronic CO(2) retention in these patients to alterations in respiratory cycle timing and to a neuromuscular inspiratory effort which is adequate for the level of tissue CO(2) production, but inadequate in the presence of mechanical and ventilation-perfusion abnormalities to normalize arterial blood gases.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7358847      PMCID: PMC434467          DOI: 10.1172/JCI109732

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  23 in total

1.  The respiratory effects of progesterone in severe pulmonary emphysema.

Authors:  J H CULLEN; V C BRUM; W U REIDT
Journal:  Am J Med       Date:  1959-10       Impact factor: 4.965

2.  The respiratory response to carbon dioxide in health and in emphysema.

Authors:  D BRODOVSKY; J A MACDONELL; R M CHERNIACK
Journal:  J Clin Invest       Date:  1960-05       Impact factor: 14.808

3.  A standardized breath holding technique for the clinical measurement of the diffusing capacity of the lung for carbon monoxide.

Authors:  W S BLAKEMORE; R E FORSTER; J W MORTON; C M OGILVIE
Journal:  J Clin Invest       Date:  1957-01       Impact factor: 14.808

4.  Respiratory and electrolyte effects induced by estrogen and progesterone.

Authors:  R L GOODLAND; J G REYNOLDS; A B MCCOORD; W T POMMERENKE
Journal:  Fertil Steril       Date:  1953 Jul-Aug       Impact factor: 7.329

5.  The rate of isometric inspiratory pressure development as a measure of responsiveness to carbon dioxide in man.

Authors:  A W Matthews; J B Howell
Journal:  Clin Sci Mol Med       Date:  1975-07

6.  Ventilatory drive and ventilatory response during rebreathing.

Authors:  N Maranetra; M C Pain
Journal:  Thorax       Date:  1974-09       Impact factor: 9.139

7.  Therapeutic use of progesterone in alveolar hypoventilation associated with obesity.

Authors:  H A Lyons; C T Huang
Journal:  Am J Med       Date:  1968-06       Impact factor: 4.965

8.  Effects of hypercapnia and inspiratory flow-resistive loading on respiratory activity in chronic airways obstruction.

Authors:  M D Altose; W C McCauley; S G Kelsen; N S Cherniack
Journal:  J Clin Invest       Date:  1977-03       Impact factor: 14.808

9.  Control of breathing in patients with chronic obstructive lung disease.

Authors:  J Sorli; A Grassino; G Lorange; J Milic-Emili
Journal:  Clin Sci Mol Med       Date:  1978-03

10.  Ventilation-perfusion inequality in chronic obstructive pulmonary disease.

Authors:  P D Wagner; D R Dantzker; R Dueck; J L Clausen; J B West
Journal:  J Clin Invest       Date:  1977-02       Impact factor: 14.808

View more
  10 in total

Review 1.  Pathophysiology of human ventilatory control.

Authors:  Jerome A Dempsey; Curtis A Smith
Journal:  Eur Respir J       Date:  2014-06-12       Impact factor: 16.671

2.  Chronic respiratory failure in COPD: is there a place for a respiratory stimulant?

Authors:  P A Bardsley
Journal:  Thorax       Date:  1993-08       Impact factor: 9.139

3.  Comparison of almitrine bismesylate and medroxyprogesterone acetate on oxygenation during wakefulness and sleep in patients with chronic obstructive lung disease.

Authors:  E Daskalopoulou; D Patakas; V Tsara; F Zoglopitis; E Maniki
Journal:  Thorax       Date:  1990-09       Impact factor: 9.139

4.  Progesterone stimulates respiration through a central nervous system steroid receptor-mediated mechanism in cat.

Authors:  D A Bayliss; D E Millhorn; E A Gallman; J A Cidlowski
Journal:  Proc Natl Acad Sci U S A       Date:  1987-11       Impact factor: 11.205

Review 5.  Chronic obstructive pulmonary disease * 9: management of ventilatory failure in COPD.

Authors:  P K Plant; M W Elliott
Journal:  Thorax       Date:  2003-06       Impact factor: 9.139

Review 6.  Chronic obstructive pulmonary disease.

Authors:  N R Anthonisen
Journal:  CMAJ       Date:  1988-03-15       Impact factor: 8.262

7.  Role of airway receptors in the breathing pattern of patients with chronic obstructive lung disease.

Authors:  A G Fennerty; J Banks; C Bevan; A P Smith
Journal:  Thorax       Date:  1985-04       Impact factor: 9.139

8.  Mechanisms underlying CO2 retention during flow-resistive loading in patients with chronic obstructive pulmonary disease.

Authors:  A Oliven; S G Kelsen; E C Deal; N S Cherniack
Journal:  J Clin Invest       Date:  1983-05       Impact factor: 14.808

9.  Oral progesterone treatment in chronic obstructive lung disease: failure of voluntary hyperventilation to predict response.

Authors:  D A Morrison; A L Goldman
Journal:  Thorax       Date:  1986-08       Impact factor: 9.139

Review 10.  Control of Ventilation in Health and Disease.

Authors:  Susmita Chowdhuri; M Safwan Badr
Journal:  Chest       Date:  2016-12-19       Impact factor: 9.410

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.